Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low  dose rate brachytherapy monotherapy

To validate the 2019 NCCN subgroups of favorable- and unfavorable-intermediate risk (IR) prostate cancer among patients treated with brachytherapy, who are underrepresented in the studies used to develop the 2019 NCCN classification.

Source: Brachytherapy - December 4, 2019 Category: Cancer & Oncology Authors: Martin C. Tom, Chandana.A. Reddy, Timothy D. Smile, Ryan X. Zhang, Jay P. Ciezki, Kevin L. Stephans, Omar Y. Mian, Eric A. Klein, Steven Campbell, James Ulchaker, Kenneth Angermeier, Rahul D. Tendulkar Source Type: research